Would the open label switch ALL subjects to Leronlimab once the 28 days are done? It feels that if it didn't that would be unkind to that group put on the placebo/SOC.

For the specifics of the test I don't know if that is how it works. However, as a human and since WE know it works or we wouldn't be here as investors, I feel that is how it should be. If we had a choice, NP better go with the latter... as I'm sure he would.